2 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 2 Not applicable, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Multiple Myeloma, Neoplasms: new trials by email Literature Review of Multiple Myeloma, Neoplasms trials Research Report on Multiple Myeloma, Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone - Peripheral Neuropathy, Multiple Myeloma, Neoplasms | Phase 4 | Recruiting | Tanta University | 44 | 2025-08-30 | 2025-11-04 |
| Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma Aponermin, pomalidomide, dexamethasone - Multiple Myeloma, Neoplasms | Not applicable | Active not recruiting | Peking University People's Hospital | 105 | 2025-03-01 | 2025-04-11 |
| 5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients Multiple Myeloma, Neoplasms | Not yet recruiting | Assiut University | 40 | 2024-12-01 | 2024-11-01 | |
| Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors Implementation of social determinants of health screening and referral - Cancer, Cancer Survivors | Not applicable | Recruiting | Barbara Ann Karmanos Cancer Institute | 120 | 2024-09-03 | 2025-08-26 |
| A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib) Multiple Myeloma, Neoplasms | Completed | Genentech, Inc. | 662 | 2012-12-01 | 2016-11-02 | |
| A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers cetuximab, vemurafenib - Multiple Myeloma, Neoplasms | Phase 2 | Completed | Hoffmann-La Roche | 208 | 2012-04-12 | 2017-11-20 |
Multiple Myeloma (6) · Neoplasms (6) · Gastrointestinal Neoplasms (1) · Neuroendocrine Tumors (1) · Peripheral Nervous System Diseases (1)
Blood Protein Disorders (6) · Cardiovascular Diseases (6) · Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Hemorrhagic Disorders (6) · Hemostatic Disorders (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphoproliferative Disorders (6) · Neoplasms by Histologic Type (6) · Neoplasms, Plasma Cell (6) · Paraproteinemias (6) · Vascular Diseases (6) · Digestive System Diseases (1) · Digestive System Neoplasms (1)
Dexamethasone (2) · Bortezomib (1) · Cetuximab (1) · Fenofibrate (1) · Lenalidomide (1) · Referral and Consultation (1) · Tablets (1) · Vemurafenib (1) · pomalidomide (1)
Assiut University (1) · Barbara Ann Karmanos Cancer Institute (1) · Genentech, Inc. (1) · Hoffmann-La Roche (1) · Peking University People's Hospital (1) · Tanta University (1)
United States (3) · China (2) · Egypt (1) · France (1) · Germany (1) · Spain (1) · United Kingdom (1)
Ashraf M Alaa, BSc of clinical pharmacy (1) · Eman Zaki, Professor (1)